Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERATION: Atezolizumab plus bevacizumab after SBRT for unresectable HCC with macrovascular invasion
jRCTs031210694Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidence of treatment-related dose-limiting toxicity (DLT) within 60 days from last day of SBRT (Safety Part) and 1-year overall survival rate (Phase II Part). Started Nov 2022; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031210694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210694.